To highlight the potential association between alopecia and drug resistance in tuberculosis treatment, emphasizing its clinical significance.
Key Findings:
Alopecia is a rare but significant adverse drug reaction associated with anti-tuberculosis treatment, particularly in drug-resistant cases.
The patient's alopecia was consistent with anagen effluvium, resolving within one month after discontinuation of isoniazid, highlighting the need for prompt recognition.
Isoniazid monoresistance was confirmed following the patient's alopecia, underscoring the importance of resistance testing.
Interpretation:
The case underscores the importance of monitoring for adverse drug reactions like alopecia during tuberculosis treatment, especially in patients with drug resistance, to improve patient outcomes.
Limitations:
The case is based on a single patient, limiting generalizability and highlighting the need for further research.
Further studies are needed to establish a broader understanding of alopecia in the context of tuberculosis treatment and its implications for clinical practice.
Conclusion:
Discontinuation of isoniazid led to hair regrowth, emphasizing the need for careful management of adverse drug reactions in tuberculosis therapy and the importance of recognizing rare ADRs.
